I'm not following?
If a trial demonstrates a benefit for < 65 (which are the majority of patients), on the primary endpoint (mortality), then why do you think this be ignored?
I'm not following?If a trial demonstrates a benefit for < 65...
-
- There are more pages in this discussion • 1,571 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.46 |
Change
0.015(1.04%) |
Mkt cap ! $1.661B | |||
| Open | High | Low | Value | Volume |
| $1.44 | $1.46 | $1.40 | $3.815M | 2.664M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 11031 | $1.45 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.46 | 14844 | 2 |
View Market Depth
| Last trade - 16.10pm 15/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |